Evogliptin Tartrate free base · Synonyms: DA-1229 tartrate

Evogliptin tartrate is an orally active DPP4 inhibitor.

For research use only. Not for human or veterinary use.

Purity >98% Stock Inquire

Data Sheet SDS COA

Evogliptin Tartrate structure

CAS No.: 1222102-51-3

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 785.00	BP-00017-50mg	In stock	Get quote
100 mg	USD 1,250.00	BP-00017-100mg	In stock	Get quote
250 mg	USD 2,250.00	BP-00017-250mg	In stock	Get quote
500 mg	USD 3,450.00	BP-00017-500mg	In stock	Get quote
1 g	Inquire	BP-00017-1g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.

Biological activity

In Vitro Evogliptin tartrate (2.49 mM; 12 h) efficiently inhibits mDPP4 (membrane DPP4) enzymatic activity in PWM-induced H9 Th1 cells. Evogliptin tartrate prevents inflammatory and fibrotic signaling through autophagy induction in primary hepatocytes of ATG7f/f-Cre+ mice. In Vivo Evogliptin tartrate (100, 300 mg/kg; in animal feedings; single daily for 10 weeks) exhibits antidiabetic effects on HFD/STZ mice and improves glucose intolerance and insulin resistance.

Identifiers

SMILES: [C@@H]([C@H](C(O)=O)O)(C(O)=O)O.C(C[C@@H](CC1=C(F)C=C(F)C(F)=C1)N)(=O)N2[C@H](COC(C)(C)C)C(=O)NCC2
InChIKey: RBBXDAJRSNHIJZ-DLDKMZOSSA-N

Specifications

MW (average): 551.5101
Formula: C₂₃H₃₂F₃N₃O₉
CAS No.: 1222102-51-3
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃, sealed storage, away from moisture<p> In solvent : -80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)</p>

Solubility

Soluble in DMSO

Documents

References

[1]. Yoon H, et al. Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells. Biomol Ther (Seoul). 2021 Mar 1;29(2):154-165.

[2]. Seo H Y, et al. Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells. International Journal of Molecular Sciences, 2022, 23(19): 11636.

[3]. Kim TH, et al. Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes. Eur J Pharmacol. 2016 Jan 15;771:65-76.

[4]. Tan X, et al. Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2016 Jun;17(9):1285-93.